Robert W. Overell、Mary G. Prieve、Michael Houston
i-ERT | Hybrid mRNA Technology |
PRX-OTC for Ornithine Transcarbamylase Deficiency (OTCD) | PRX-ASL for ArgininosuccinateLyase Deficiency (ASLD) |
融资轮次 | 融资日期 | 投资方 | 融资额度 |
---|---|---|---|
A轮 | 2008-02 | 5AM Ventures、ARCH Venture Partners、Versant Ventures | $20.22M |
A+轮 | 2009-08 | 未披露 | $302.65k |
债务融资 | 2012-02 | 未披露 | $3.6M |
债务融资 | 2012-12 | 未披露 | $1.5M |
债务融资 | 2013-10 | 未披露 | $1.4M |
债务融资 | 2015-12 | 未披露 | $4M |